{"id":"teriflunomide-hmr1726","safety":{"commonSideEffects":[{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Elevated liver enzymes"},{"rate":"null","effect":"Alopecia"},{"rate":"null","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL973","moleculeType":"Small molecule","molecularWeight":"270.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking dihydroorotate dehydrogenase, teriflunomide depletes pyrimidine nucleotides needed for DNA and RNA synthesis, selectively suppressing the proliferation of T and B lymphocytes that depend on de novo pyrimidine synthesis. This immunosuppressive effect reduces the inflammatory cascade in autoimmune diseases. The drug is the active metabolite of leflunomide and has a long half-life allowing once-daily dosing.","oneSentence":"Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:44.367Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Secondary progressive multiple sclerosis (SPMS)"}]},"trialDetails":[{"nctId":"NCT04799288","phase":"PHASE1, PHASE2","title":"Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2021-09-24","conditions":"HAM/TSP","enrollment":24},{"nctId":"NCT06141473","phase":"PHASE3","title":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-13","conditions":"Multiple Sclerosis","enrollment":1600},{"nctId":"NCT06372145","phase":"PHASE3","title":"A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-04-16","conditions":"Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis","enrollment":2500},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT06176235","phase":"PHASE2","title":"Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia","status":"WITHDRAWN","sponsor":"Peking University People's Hospital","startDate":"2023-12-19","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT04410991","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-11","conditions":"Relapsing Multiple Sclerosis","enrollment":899},{"nctId":"NCT04410978","phase":"PHASE3","title":"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":974},{"nctId":"NCT04338022","phase":"PHASE3","title":"Study of Evobrutinib in Participants With RMS (evolutionRMS 1)","status":"TERMINATED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2020-06-12","conditions":"Relapsing Multiple Sclerosis","enrollment":1124},{"nctId":"NCT04338061","phase":"PHASE3","title":"Study of Evobrutinib in Participants With RMS (evolutionRMS 2)","status":"TERMINATED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2020-07-02","conditions":"Relapsing Multiple Sclerosis","enrollment":1166},{"nctId":"NCT02201108","phase":"PHASE3","title":"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-07-16","conditions":"Multiple Sclerosis","enrollment":166},{"nctId":"NCT05112484","phase":"","title":"Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-06","conditions":"Multiple Sclerosis","enrollment":600},{"nctId":"NCT06190145","phase":"PHASE2","title":"Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-12-05","conditions":"Immune Thrombocytopenia","enrollment":40},{"nctId":"NCT06176911","phase":"PHASE2","title":"The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-12-05","conditions":"Immune Thrombocytopenia","enrollment":124},{"nctId":"NCT03198351","phase":"","title":"An Observational Study on Teriflunomide-exposed Pregnancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-04-25","conditions":"Multiple Sclerosis","enrollment":220},{"nctId":"NCT03856619","phase":"PHASE4","title":"To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-27","conditions":"Relapsing Multiple Sclerosis","enrollment":121},{"nctId":"NCT03122652","phase":"PHASE3","title":"Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-09-25","conditions":"Multiple Sclerosis","enrollment":125},{"nctId":"NCT03768648","phase":"NA","title":"Cognition and MRI Markers in MS Patients With Aubagio® Treatment","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2019-05-21","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":75},{"nctId":"NCT01970410","phase":"PHASE4","title":"MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2013-10","conditions":"Multiple Sclerosis","enrollment":55},{"nctId":"NCT03464448","phase":"","title":"Mechanistic Studies of Teriflunomide in RRMS","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-04-17","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":30},{"nctId":"NCT04676204","phase":"","title":"Relationship Between Oral DMT Burden and Adherence in MS","status":"ENROLLING_BY_INVITATION","sponsor":"Monash University","startDate":"2020-09-25","conditions":"Multiple Sclerosis, Adherence, Medication","enrollment":323},{"nctId":"NCT05075499","phase":"NA","title":"Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2021-03-20","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT02651545","phase":"","title":"Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2014-02","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT02490982","phase":"","title":"Teriflunomide Observational Effectiveness Study","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2015-11","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":106},{"nctId":"NCT03561402","phase":"","title":"Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)","status":"COMPLETED","sponsor":"McGill University","startDate":"2016-12-01","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":24},{"nctId":"NCT03526224","phase":"","title":"Teriflunomide Tecfidera LMCE","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2018-06-14","conditions":"Tecfidera, Teriflunomide","enrollment":120},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT02263547","phase":"PHASE1","title":"Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride","status":"TERMINATED","sponsor":"Derrick Scott Robertson","startDate":"2015-03","conditions":"Teriflunomide Elimination, Healthy Volunteers","enrollment":14},{"nctId":"NCT02776072","phase":"","title":"Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-05","conditions":"Multiple Sclerosis","enrollment":2978},{"nctId":"NCT00622700","phase":"PHASE3","title":"Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-02","conditions":"Multiple Sclerosis","enrollment":618},{"nctId":"NCT00803049","phase":"PHASE3","title":"Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Multiple Sclerosis","enrollment":742},{"nctId":"NCT01895335","phase":"PHASE4","title":"Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Multiple Sclerosis","enrollment":1001},{"nctId":"NCT00751881","phase":"PHASE3","title":"An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-08","conditions":"Multiple Sclerosis","enrollment":1169},{"nctId":"NCT00883337","phase":"PHASE3","title":"A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Multiple Sclerosis","enrollment":324},{"nctId":"NCT01403376","phase":"PHASE2","title":"Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-09","conditions":"Multiple Sclerosis","enrollment":128},{"nctId":"NCT01881191","phase":"","title":"Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2013-06","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT00228163","phase":"PHASE2","title":"Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-01","conditions":"Multiple Sclerosis","enrollment":147},{"nctId":"NCT01863888","phase":"PHASE3","title":"Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-10","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT02046629","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-05","conditions":"Multiple Sclerosis","enrollment":12},{"nctId":"NCT01252355","phase":"PHASE3","title":"Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta","status":"TERMINATED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Multiple Sclerosis Relapse","enrollment":534},{"nctId":"NCT00134563","phase":"PHASE3","title":"Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Multiple Sclerosis","enrollment":1088},{"nctId":"NCT00811395","phase":"PHASE2","title":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":182},{"nctId":"NCT00475865","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-04","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT00489489","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":118},{"nctId":"NCT01487096","phase":"PHASE2","title":"Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-04","conditions":"Multiple Sclerosis","enrollment":179},{"nctId":"NCT01239459","phase":"PHASE1","title":"Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Renal Impairment","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aubagio"],"phase":"marketed","status":"active","brandName":"Teriflunomide HMR1726","genericName":"Teriflunomide HMR1726","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes. Used for Relapsing-remitting multiple sclerosis (RRMS), Secondary progressive multiple sclerosis (SPMS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}